Glioblastoma, IDH-Wildtype — Trials

Glioblastoma, IDH-Wildtype — Trials · CancerIndex

Clinical trials

Registered studies

303 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 76
Recruiting: 42
Ph III recruiting: 3
Growth YoY: —
Industry share: 12%
Top sponsor: Mayo Clinic
Termination share: 43.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (64)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07655869	[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma	recruiting	Early Phase 1	24	Beijing Tiantan HospitalOTHER	1	Jun 18, 2026	clinicaltrials
NCT07648823	Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma	recruiting	Early Phase 1	5	Beijing Tiantan HospitalOTHER	1	Jun 16, 2026	clinicaltrials